Group 1 - Shanghai Municipal Medical Procurement Management Office has suspended the procurement qualifications for two drugs due to non-compliance with price adjustment requirements: hydrochloride dobutamine injection produced by Anhui Changjiang Pharmaceutical Co., Ltd. and hydrochloride arginine injection produced by Jilin Huinan Changlong Biochemical Pharmaceutical Co., Ltd [1] - Both drugs are classified as shortage drugs, with multiple companies having obtained approval numbers for these products in China [1] - The national average price for hydrochloride dobutamine injection (2ml:20mg) is reported at 3.53 yuan per unit, while hydrochloride arginine injection (20ml:5g) is at 11.68 yuan per unit [1] Group 2 - The management mechanism for shortage drugs in China is improving, with the State Council issuing opinions in 2019 to ensure the supply and price stability of these drugs [2] - The average delivery rate for drugs on the national shortage list has increased from approximately 60% before 2019 to 90% currently [2] - New issues have emerged, including some companies creating artificial shortages to justify price increases, particularly at the local level [2] Group 3 - In August 2024, several national departments issued a notice to strengthen monitoring of production reserves for shortage drugs and those selected for centralized procurement [3] - A total of 109 shortage drug formulations, 60 raw materials, and 240 nationally selected drugs are under production reserve monitoring, with dynamic adjustments to the monitoring list [3] - The National Medical Insurance Administration has issued guidelines for risk management of shortage drug prices, focusing on price information disclosure, analysis, and monitoring [3]

Core Viewpoint - The suspension of procurement qualifications for two critical shortage drugs, Dobutamine Hydrochloride Injection and Arginine Hydrochloride Injection, due to failure to reduce prices, highlights the ongoing challenges in ensuring supply and stabilizing prices in the shortage drug market [1][2][10]. Group 1: Drug Details - Dobutamine Hydrochloride Injection, produced by Anhui Changjiang Pharmaceutical, is essential for treating acute heart failure and is packaged in 2ml:20mg vials [3][4]. - Arginine Hydrochloride Injection, produced by Jilin Province Huinan Changlong Biochemical Pharmaceutical, is crucial for treating hepatic encephalopathy and is packaged in 20ml:5g vials [3][4]. - The average national price for Dobutamine Hydrochloride Injection is reported at 3.53 yuan per unit, while Arginine Hydrochloride Injection is at 11.68 yuan per unit [9]. Group 2: Market Dynamics - The recent price increases for shortage drugs, including the significant rise in the price of the rare disease drug Hydrocortisone Acetate Tablets, reflect ongoing supply and demand imbalances, regulatory challenges, and regional price disparities [2][10][12]. - The production of Dobutamine Hydrochloride Injection is not limited to Anhui Changjiang Pharmaceutical; other companies like Hainan Puli Pharmaceutical and Shandong Xinhua Pharmaceutical have also entered the market, enhancing competition [5][6]. - The procurement suspension serves as a warning to pharmaceutical companies that they must consider drug accessibility and price rationality in their pricing strategies to avoid market constraints [9][11]. Group 3: Regulatory Environment - The regulatory landscape for shortage drugs has evolved from self-pricing to risk management, with recent policies allowing companies to set reasonable prices while emphasizing the need to prevent unreasonable price hikes and monopolistic practices [11][12]. - Various regions, including Chongqing and Guangdong, are exploring centralized procurement for shortage and emergency drugs to stabilize prices and ensure supply [12].

【导读】稳定币概念股强势走高，胜利证券一度涨超160% 中国基金报记者李智 6月26日上午，A股三大指数小幅上涨，截至午间收盘，沪指涨0.11%，深成指涨0.26%，创业板指涨0.31%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3459.66 | 10420.86 | 1455.45 | | +3.68 +0.11% | +27.14 +0.26% | +17.83 +1.24% | | 科创50 | 创业板指 | 万得全A | | 1000.39 | 2134.99 | 5299.91 | | +4.78 +0.48% | +0.31% +6.59 | +17.18 +0.33% | 板块上来看，航天军工板块持续爆发，稳定币板块强势走高，软件、固态电池、化工等板块涨幅居前；生物医药、汽车、券商等板块震荡调整。 | | | Wind热门概念指数 | | | | | Wind中国行业指数 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 稳定币 4.45% | 军工信息化 ...

【导读】稳定币概念股强势走高，胜利证券一度涨超 160% 中国基金报记者 李智 6 月 26 日上午， A 股三大指数小幅上涨，截至午间收盘，沪指涨 0.11% ，深成指涨 0.26% ，创业板指涨 0.31% 。 | 上证指数 | | 深证成指 | 北证50 | | --- | --- | --- | --- | | 3459.66 | | 10420.86 | 1455.45 | | +3.68 +0.11% | +27.14 +0.26% | | +17.83 +1.24% | | 科创50 | 创业板指 | | 万得全A | | 1000.39 | 2134.99 | | 5299.91 | | +4.78 +0.48% | +6.59 | +0.31% | +17.18 +0.33% | 板块上来看，航天军工板块持续爆发，稳定币板块强势走高，软件、固态电池、化工等板块 涨幅居前；生物医药、汽车、券商等板块震荡调整。 | | | Wind热门概念指数 | | | | | Wind中国行业指数 | | | | --- | --- | --- | --- | --- | --- | --- | --- | ...

Group 1: Cobalt Market - The Democratic Republic of Congo (DRC) has extended the temporary ban on cobalt exports for an additional three months due to high inventory levels, affecting all sources of cobalt mining [1] - According to USGS, global cobalt production in 2024 is estimated at 288,000 metric tons, with DRC contributing approximately 220,000 metric tons, a year-on-year increase of about 25%, representing 76.4% of the global market [1] - The extended ban is expected to impact global cobalt supply by over 100,000 metric tons this year, potentially leading to domestic supply shortages [1] Group 2: Cross-Border Payment - The launch of the "Cross-Border Payment Pass" on June 22 marks the realization of interconnectivity between the mainland and Hong Kong's rapid payment systems, allowing real-time cross-border remittances [2] - This innovation is anticipated to enhance the convenience of using the Renminbi in cross-border retail scenarios and further promote the internationalization of the Renminbi [2] - Analysts suggest that the "Cross-Border Payment Pass" and stablecoins will serve as new engines for industry development, improving cross-border transaction efficiency and supporting global financial governance [2] Group 3: Brain-Computer Interface - The first intervention-based brain-computer interface trial for restoring motor function in a paralyzed patient has been successfully completed in China, showcasing the country's innovation in core brain-computer interface technology [3] - Analysts believe that brain-computer interfaces are poised to become a core technology for human-machine interaction, with applications initially focused on medical rehabilitation and later expanding to education, entertainment, military, and industrial sectors [3][4] Group 4: High-End Medical Devices - The National Medical Products Administration has approved measures to optimize the lifecycle regulation of high-end medical devices, supporting innovation in this sector [5] - The measures include optimizing special approval processes, improving classification and naming principles, and enhancing post-market surveillance [5] - The high-end medical device market is expected to grow significantly, with projections indicating a market size of 1.27 trillion yuan in 2023, surpassing 1.8 trillion yuan by 2025, and reaching 3 trillion yuan by 2030, with a compound annual growth rate exceeding 11.5% [5][6] Group 5: Smart Factories - The Ministry of Industry and Information Technology has announced the 2025 action plan for cultivating smart factories, categorizing them into four levels: basic, advanced, excellent, and leading [6] - Smart factories are seen as the core vehicle for the digital transformation of manufacturing, integrating information technology, automation, and artificial intelligence to achieve intelligent and efficient production processes [6] - The smart factory market is projected to exceed 1.4 trillion yuan by 2025, with a compound annual growth rate of over 10%, and is expected to approach 4.5 trillion yuan by 2030 [6]

Market Overview - On June 20, A-shares continued to decline, with the Shanghai Composite Index down 0.07% at 3359 points, the Shenzhen Component Index down 0.47%, and the ChiNext Index down 0.83%. Over 3600 stocks in the market fell [1] - Market focus shifted to sectors such as composite fluid, shipping ports, and banking [1] High-Performing Stocks - Shandong Molong achieved a six-day consecutive rise, closing up 10.03% at 7.02, driven by oil and gas equipment, shale gas, and state-owned enterprise themes [4][12] - Nord Shares, a solid-state battery concept stock, recorded a four-day consecutive rise, closing up 10.04% at 5.15 [4][12] - Chutianlong staged a "limit-up" performance at the end of the trading day, achieving a three-day consecutive rise with a 10.00% increase, closing at 23.33 [4][12] Stock Performance Data - The following stocks showed significant gains: - Shandong Molong: +10.03%, 6 consecutive days [4] - Nord Shares: +10.04%, 4 consecutive days [4] - Chutianlong: +10.00%, 3 consecutive days [4] - Other notable stocks include: - ST Yingfit: +4.86%, 4 days 3 boards [4] - ST Xintong: +5.03%, 4 days 3 boards [4] - Jianglong Shipbuilding: +20.00%, 2 consecutive days [6] Trading Activity - The top three net buying stocks on the Dragon and Tiger list were: - Keheng Shares: 183 million [5] - Qiangli New Materials: 165 million [5] - Chutianlong: 164 million [5] - The top three net selling stocks were: - Innovation Medical: 172 million [7] - Hengbao Shares: 135 million [7] - Yong'an Pharmaceutical: 74 million [7] Sector Highlights - The fifth China International Solid-State Battery Technology Conference will be held on June 19-20, 2025, indicating a push towards solid-state battery industrialization [12] - Shandong Molong's revenue from oil pipes and casings accounted for 90.73% of its total revenue, with overseas exports growing over 25% year-on-year [15] - Sai Sheng Pharmaceutical's recent contract for new drug technology transfer aims to enhance its pipeline in the cardiovascular field [18]

Group 1: Institutional Trading Insights - On the institutional trading leaderboard, 28 stocks were listed, with 16 experiencing net buying and 13 facing net selling [1] - The top three stocks with the highest institutional buying were: Limin Co., Ltd. (75.16 million), Saiseng Pharmaceutical (71.78 million), and Haike Xinyuan (37.08 million) [1] Group 2: Stock Performance and Market Trends - Limin Co., Ltd. saw a decrease of 9.98% with a net buying amount of 105 million [2] - Saiseng Pharmaceutical experienced a significant increase of 19.97% with a net buying amount of 57.49 million [2] - Haike Xinyuan had a notable rise of 20.00% with a net buying amount of 37.09 million [2] Group 3: Industry Developments - Saiseng Pharmaceutical's subsidiary, Junyuan Pharmaceutical, produces ursodeoxycholic acid tablets, indicating a focus on relevant production capabilities [3] - The solid-state battery sector is advancing, with companies like Kexin and Taiblue New Energy developing new materials and products for battery applications [3] - The Ministry of Industry and Information Technology is expected to conduct a mid-term review of solid-state battery projects by the end of 2025, with key developments anticipated between 2025 and 2026 [3] Group 4: Market Opportunities in Advanced Packaging - The advanced packaging market is projected to grow from 30.4 billion in 2020 to approximately 47.5 billion by 2026, increasing its market share from 45% to 50% [5]

Group 1 - The innovative drug concept is experiencing a volatile rebound, with Sai Sheng Pharmaceutical (300485) hitting a 20% limit up, while companies like Anglikang (002940), Watson Bio (300142), Yuekang Pharmaceutical, Saint Nuo Bio, and Rongchang Bio also saw significant gains [1] - There is a disclosure of dark pool fund flows, indicating early signals of stock accumulation by major investors [1]

Group 1 - Shengnuo Bio expects a net profit attributable to shareholders of 77.03 million to 94.14 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - The significant growth in Shengnuo Bio's performance is primarily attributed to the strong performance of its peptide raw material business, which is closely related to GLP-1 formulations [1] Group 2 - Shanghai Laishi has completed the acquisition of 100% equity in Nanyue Bio for 4.2 billion yuan, with an additional contingent payment of 50 million yuan if the company processes 305 tons of plasma by 2025 [2] - The completion of the acquisition and registration marks a significant step forward in Shanghai Laishi's "plasma expansion" strategy, although it is expected to add substantial goodwill, raising concerns about future impairment risks [2] Group 3 - Beijing Saisheng Pharmaceutical has signed a new drug technology transfer agreement with its affiliate, transferring technology related to the NeoAB33 new drug project for a total of 20 million yuan [3] - The transfer may optimize the asset structure of Huada Protein, which reported a loss of 8.3 million yuan in 2024, while Saisheng Pharmaceutical reported a net profit of 39.97 million yuan in the first quarter of 2025, indicating its financial capability to advance research and development [3] Group 4 - Eli Lilly's reversible BTK inhibitor, Pirtobrutinib, has had its new indication application accepted for review in China, targeting patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received BTK inhibitor treatment [4] - If approved, Pirtobrutinib will provide a new treatment option for patients who have failed previous covalent BTK inhibitor therapies, further solidifying its market position in the treatment of B-cell malignancies [4] Group 5 - Innovent Biologics' CLDN-18.2 ADC product, IBI343, is proposed to be included as a breakthrough therapy for locally advanced or metastatic pancreatic cancer expressing CLDN 18.2, after at least two systemic treatments [5] - As the first CLDN18.2 ADC to achieve a breakthrough in pancreatic cancer, IBI343 is expected to fill a gap in second-line and later treatments, providing new options for patients [5]

Core Viewpoint - Multiple companies have announced significant developments, including investments, clarifications on business operations, and changes in control, which may present various investment opportunities and risks for stakeholders [2]. Company Announcements - **Hai Zheng Pharmaceutical** plans to establish a joint venture in synthetic biology with a registered capital of 350 million yuan, where Hai Zheng will contribute 260 million yuan, holding a 74.29% stake [3]. - **Jin Zhong Zi Jiu** clarified that its business scope remains unchanged despite media reports suggesting a shift away from liquor production, confirming that it will continue to focus on its core liquor business [4]. - **ST Gong Zhi** announced that its stock will resume trading on June 20, 2025, and enter a delisting period, with the last trading date expected to be July 10, 2025 [5]. - **Zhong Jing Electronics** confirmed that its production and operational conditions are normal, with no undisclosed significant matters [6]. - **Shan Jin International** is preparing for an overseas H-share issuance and listing on the Hong Kong Stock Exchange to enhance its global strategy [7]. - **Kang Da New Materials** intends to acquire at least 51% of Chengdu Zhongke Huamei Electronics to expand into the semiconductor integrated circuit sector [8]. - **Zhong Yan Chemical** agreed to a capital reduction for its subsidiary, which will result in it holding 100% of the subsidiary's equity, constituting a significant asset restructuring [9]. - **Tai Ji Co., Ltd.** announced a change in its actual controller to the Hubei Provincial State-owned Assets Supervision and Administration Commission, with stock resuming trading [10]. - **ST Yi Guo** plans to sell four Carrefour subsidiaries for 1 yuan, expecting to increase its net profit by approximately 572 million yuan, while focusing on its core home appliance business [11][12]. Performance Expectations - **Sheng Nuo Bio** anticipates a substantial increase in net profit for the first half of 2025, projecting a year-on-year growth of 253.54% to 332.10%, driven by strong performance in its peptide raw material business [13]. Share Buyback - **Nuo Wei Zan** intends to repurchase shares worth between 5 million and 10 million yuan to implement employee stock ownership plans, with a maximum repurchase price of 30 yuan per share [14]. Major Contracts - **Sai Sheng Pharmaceutical** signed a technology transfer contract for a new drug project with a total transaction amount of 20 million yuan, which will enhance its capabilities in the protein/antibody drug platform [15].